Introduction
How to compare different drugs?
The choice of an adequate treatment for neuropathic Diabetic neuropathies may impair quality of life, they are both prognostically and pathogenetically important pain should take into account proven efficacy, number and severity of adverse events, toxicity, pharmacofactors for the development of the diabetic foot syndrome and associated with a reduced life expectancy. kinetics, contraindications, limitations for treatment due to comorbid conditions, and-last not leastImprovement of metabolic control over the years has been proven to reduce the incidence of diabetic neuro-costs. Obviously, it is difficult to compare all these variables for the drugs to be described later, since there pathy in type 1 [1] and presumably also in type 2 diabetic patients [2, 3] . In the near future, besides is no common denominator for efficacy, and only in rare instances have different drugs been compared intensified diabetes treatment, metabolic steps important in the pathogenesis of diabetic neuropathy may be directly. A rough estimate of efficacy may be the number of patients needed to treat (NNT ) to obtain targeted by specific drugs effectively inhibiting the accumulation of sorbitol, reducing oxidative stress, a substance specific beneficial effect in one patient [4] .
Direct comparisons are, however, hampered by the stopping the formation of advanced glycation end products, improving nerve blood flow, reversing fact that NNT's are derived from studies with different durations of drug treatment and with different endpochanges in membrane lipid metabolism, or substituting nerve growth factors. At present, and in the forseeable ints which may not be directly comparable. The relevance of the NNT is further weakened by the fact that future, it seems to be impossible to completely eliminate the development of neuropathic diabetic lesions due to the small number of patients included in most studies, the 95% confidence intervals are sometimes because normoglycaemia is achieved in only a small part of all patients. This implicates that neuropathy extremely large. Consequently, the differences of NNT's for different substances that have been found will remain a clinical problem for the years to come. Besides intensive treatment of diabetes which is indi-are frequently not statistically significant. Clearly, in clinical practice, the apparent response to a given drug cated in all patients at risk, additionally symptomatic treatment is necessary in some patients with neuro-is much better than indicated by the NNT, because not only specific but also unspecific effects including pathic pain. The prevalence of symptomatic distal symmetrical polyneuropathy, being the predominant placebo effects are observed [5] . cause of neuropathic pain in diabetic patients, ranges from 20 to 40%. The proportion of patients suffering from pain not treatable with simple analgesics and thus requiring specialized care is largely unknown.
Physical measures
Since diabetic micro-and macroangiopathic complications cluster in patients, it is the patient with diabetic As the first step in treating neuropathic pain it is useful nephropathy who is particularly in need of treatment to apply physical measures even though the effects of for neuropathic pain.
application of creams, massage, and cold and warm applications are difficult to quantitate. Acupuncture and transcutaneous electrical neural stimulation have Correspondence and offprint requests to: Dieter Luft, MD, been tested in a few trials and despite the difficulties Medizinische Klinik und Poliklinik der Eberhard-Karls-Universität, in designing really controlled, blinded studies, are believed to provide specific relief of pain.
Normoglycaemic metabolic control Anticonvulsants
Anticonvulsants were introduced into the treatment of Normalization of hyperglycaemia is recommended for the treatment of pain based on the results of uncon-neuropathic pain in the sixties based on uncontrolled trials. The first substance was diphenylhydantoin trolled clinical studies [6, 7] , anectodal evidence and animal experiments. Systematic controlled trials to (300 mg/d), the beneficial effect of which has not been unequivocally proven. Carbamazepine (600 mg/d) was prove this effect have not been performed. A comparably large number of anectodal reports describe painful investigated more intensively and was found to be effective. The NNT is 2-4, the NNH 2-5 [11]. symptoms after rapid improvement of metabolic control. Regrettably, pain reduction was not measured as Recently, gabapentine has been investigated. The daily dose in most patients was 3600 mg though the mean an outcome in the large clinical trials which aimed to quantitate the effects of near normalization of glyca-effective dose may be much lower. Gabapentin has been shown to significantly reduce neuropathic pain in emic control on the development of late complications. Moreover, in most studies of combined pancreas-kid-diabetic patients (NNT 4, NNH 5) [12] . ney transplantion the effect of normoglycaemia on symptoms, especially on pain, was not investigated [8] .
Since normalization of glycaemic control has been Antiarrhythmic drugs proven to reduce the incidence of neuropathic lesions in type 1 and type 2 diabetic patients, it should certainly Antiarrhythmics (a single dose of 5 mg/kg lidocaine be part of the treatment programme.
i.v. or daily doses of 450-600 mg mexiletine orally) have been investigated in diabetic patients. Mexiletine did not influence all endpoints in all trials. In retrospective evaluations, its effect was best on stabbing,
Tricyclic antidepressants
heat and burning sensations [13] . The NNT was about 2 if a significant effect was observed. The NNH was 5-10. Since mexiletine may have proarrhythmic effects Tricyclic antidepressants, e.g. imipramine, amitriptyit is problematic to use this substance in diabetic line, clomipramine and desipramine, have been investipatients with macroangiopathic complications. In the gated in randomized, placebo-controlled, cross-over reported trials cardiac adverse events were not trials of 2-6 weeks duration with mean doses around observed, but given the small number of patients 75-100 mg/d. NNT's were found to be 1.3-5, the NNT investigated this does not exclude substantial side to get one adverse event, the 'NNH' (number of effects. patients needed to harm), was about 2 [9]. Since the plasma half-life of all tricyclic antidepressants is rather long (12-22 h) it is prudent to increase the daily dose Capsaicin no more frequently than on a weekly basis. Besides the well known side effects of tricyclic antidepressants (sedative, anticholinergic, orthostatic, cardiac and con-Contrary to all drugs described which are used systemvulsive effects, and weight gain) which vary between ically and therefore lead to systemic side effects, capthe above mentioned substances one should keep in saicin, a chili pepper ingredient, topically applied four mind that the use of these substances increases the times daily as a 0.075% cream, may reduce neuropathic incidence of hip fractures [10] and suppresses heart pain in diabetic patients. The NNT is 3-5, the NNH rate variability. The long term impact of this change is 2-3 [14]. The effect achieved is comparable with in autonomic tone on life expectancy is not known. that of amitripyline [15] . The high rate of adverse The combination of tricyclic antidepressants with neur-events is caused by the initially increased pain sensation oleptic drugs has not been proven to be superior to in the creamed areas, the unintentional contamination the monotherapy.
of mucous membranes like conjunctivae, and the inhalation of dried cream particles. Systemic adverse events do not occur although long term toxic effects on nerve endings are not yet totally excluded.
Selective serotonin reuptake inhibitors a-Lipoic acid
The number of trials to prove the efficacy of selective serotonin reuptake inhibitors for pain treatment in diabetic patients is rather small. Paroxetine and citalop-In Germany, a-lipoic acid (daily 600-1200 mg/d i.v.) was shown to effectively reduce pain in diabetic patients rame (40 mg/d each) revealed NNT's of 2-5 whereas fluoxetine had no significant effect compared to pla- [16 ] . The NNT was 4-5. Adverse events were not observed in the group treated with 600 mg and were cebo. These substances are better tolerated, have less significant side effects and do not suppress heart rate negligible in the group treated with 1200 mg. It remains to be seen whether oral treatment may be equally variability, but surprisingly also increase the incidence of hip fractures [10] .
effective and how long the effect may remain stable after cessation of therapy. Ongoing studies will soon be carefully adjusted to residual renal function. Cognitive impairment may be expected in patients answer these questions. treated with tricyclic antidepressants, mexiletine and gabapentin. Looking at costs of treatment, in Germany they are lowest for tricyclic antidepressants and carOpioids bamazepine, followed by mexiletine, capsaicine, gabapentin and selective serotonin reuptake inhibitors and Although opiates and opioids are believed to be effectare highest for a-lipoic acid. Last not least, medicolegal ive means to treat neuropathic pain in diabetic patients, considerations should be mentioned: most substances this was not formally investigated before 1998 when are not approved for the treatment of neuropathic tramadol (mean effective dose 210 mg/d orally) was pain by national regulatory authorities. Doctors should shown to be superior to placebo [17] . Fentanyl was inform their patients thoroughly about the substance shown to be effective in neuropathic pain syndromes.
used, obtain informed consent, and watch carefully This study, however, did not include diabetic patients.
beneficial effects and adverse events. 
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